Den Rozhnovsky / Shutterstock.com

18 February 2025NewsAmericasMarisa Woutersen

Apple voids Omni MedSci wearable tech patent

Patent Trial and Appeal Board rules all challenged claims were unpatentable | Decision follows Federal Circuit review that revived Apple’s challenge.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Whoop faces suit over tech in health tracker watch

6 February 2025 Popular fitness tracker device accused of infringing patents owned by Omni MedSci | Plaintiff previously sued Apple over Apple Watch.

Raising the pulse: How Masimo v Apple changed patent strategy

5 March 2024 The drama of the decade-long patent dispute reflects a changing market. Marisa Woutersen speaks with John Cronin and Pete Conley from Know Labs to explore its impact on patent strategy and the changing face of medtech.

More on this story

Whoop faces suit over tech in health tracker watch

6 February 2025 Popular fitness tracker device accused of infringing patents owned by Omni MedSci | Plaintiff previously sued Apple over Apple Watch.

Raising the pulse: How Masimo v Apple changed patent strategy

5 March 2024 The drama of the decade-long patent dispute reflects a changing market. Marisa Woutersen speaks with John Cronin and Pete Conley from Know Labs to explore its impact on patent strategy and the changing face of medtech.

More on this story

Whoop faces suit over tech in health tracker watch

6 February 2025 Popular fitness tracker device accused of infringing patents owned by Omni MedSci | Plaintiff previously sued Apple over Apple Watch.

Raising the pulse: How Masimo v Apple changed patent strategy

5 March 2024 The drama of the decade-long patent dispute reflects a changing market. Marisa Woutersen speaks with John Cronin and Pete Conley from Know Labs to explore its impact on patent strategy and the changing face of medtech.

More features

Hikma warns SCOTUS of ‘imminent threat’ for generic competition under ‘skinny label’ rules

Gilead deal staves off generic HIV drugs for another six years

Clifford Chance expands life sciences team with A&O Shearman hire

Vidal: ‘Erroneous’ jury instructions need to be fixed at Fed Circ

'A very good decision’: Patent industry welcomes UPC in-house reps update

Make a difference: Cast your vote in IP Diversity & Inclusion Awards 2025

Courtroom report: Regeneron’s $6bn biosimilar battle against Mylan

Fed Circ ruling on Wuhan import ban shakes up economic prong analysis